Efficacy of tocilizumab therapy in severe COVID-19 pneumonia patients and determination of the prognostic factors affecting 30 days mortality

Creative Commons License

Delen L., Kasapoglu U. S., Gok A., Cagasar O., TETİK B., Oksuz E.

MARMARA MEDICAL JOURNAL, vol.35, no.3, pp.308-315, 2022 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 3
  • Publication Date: 2022
  • Doi Number: 10.5472/marumj.1191126
  • Journal Name: MARMARA MEDICAL JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.308-315
  • Keywords: SARS-CoV-2, COVID-19, Tocilizumab, Viral pneumonia, Cytokine storm, Prognostic factors, CYTOKINE STORM, PATHOGENESIS
  • Inonu University Affiliated: Yes

Abstract

Objective: In coronavirus disease - 19 (COVID-19) patients, cytokine storm develops due to the increase of pro-inflammatory cytokines. Tocilizumab (TU.), has been used in the treatment of COVID-19 patients and successful results have been obtained. The aim of this study was to determine the efficacy of TCZ and also investigate the prognostic factors affecting the success of treatment and mortality in COVID-19 patients treated with TCZ.